What is the expected growth forecast for the Molecular Diagnostics Point of Care market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Molecular Diagnostics Point of Care market?

Increasing demand for rapid diagnostics and technological advancements drive the market.

What are the major challenges facing the Molecular Diagnostics Point of Care market?

High development costs and regulatory hurdles are significant challenges.

Which regions are leading the Molecular Diagnostics Point of Care market?

North America and Europe are current regional leaders.

Who are the top companies in the Molecular Diagnostics Point of Care market?

Major players include Roche, Abbott, and BioMerieux.

What are the future opportunities in the Molecular Diagnostics Point of Care market?

Emerging economies and increasing demand for point-of-care testing offer future opportunities.

How will technology impact the Molecular Diagnostics Point of Care market future outlook?

Advances in molecular diagnostics will drive market growth and innovation.

What is the current regulatory landscape for the Molecular Diagnostics Point of Care market?

Stringent regulations and standards govern the market, ensuring safety and efficacy.

Molecular Diagnostics Point of Care Market Comprehensive Report: 200+ Pages | 2026–2034

Molecular Diagnostics Point of Care by Application (Tumor, Hematology, Endocrinology, Infectious Disease, Others), by Types (Assays and Kits, Instruments and Analyzers, Software and Services, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $23.6 million

CAGR: 8.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $23.6 million

CAGR: 8.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Molecular Diagnostics Point of Care Market Overview

The Molecular Diagnostics Point of Care market refers to the industry that provides innovative, portable, and user-friendly testing solutions for various diseases and health conditions. As the Molecular Diagnostics Point of Care market size is expected to reach $5.4 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion. The scope of this market encompasses point-of-care molecular diagnostic devices, assays, and software, which are used to diagnose and monitor diseases such as infectious diseases, genetic disorders, and cancer. The current Molecular Diagnostics Point of Care market size is approximately $3.4 billion, with a growth forecast of 10.3% Compound Annual Growth Rate (CAGR) from 2026 to 2033, driven by macro drivers such as increasing demand for point-of-care testing, advancements in molecular diagnostics technologies, and rising awareness about personalized medicine.

Loading chart…

The key forces shaping the industry include technology shifts towards miniaturization and automation, regulations such as the Clinical Laboratory Improvement Amendments (CLIA), and consumer behavior driven by the increasing demand for point-of-care testing. The largest region in the Molecular Diagnostics Point of Care market is North America, while the fastest-growing region is Asia-Pacific. The competitive intensity in this market is high, with major players such as Roche, Abbott, and BioMérieux competing for market share. Overall, the Molecular Diagnostics Point of Care market is expected to experience significant growth in the coming years, driven by the increasing demand for point-of-care testing and advancements in molecular diagnostics technologies.

Report Overview

Report Attribute	Details
Market size value in 2025	23.60 million
Revenue forecast in 2033	46.68 million
Growth rate	CAGR of 8.9% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Abaxis; Bayer Healthcare; Bio-Rad Laboratories; Becton Dickinson and Company; Binx Health; BioMerieux; Co-Diagnostics; Danaher Corporation; Dako; F. Hoffmann-La Roche; OraSure Technologies; Roche Diagnostics; Nipro Diagnostics; Genstat; Meridian Bioscience; Molbio Diagnostics; Siemens Healthcare; Thermo Fisher Scientific; Visby Medical; Wuhan Easy Diagnosis Biomedicine; Beijing Tiandz; Beijing Content
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Molecular Diagnostics Point of Care market is poised for significant growth, driven by factors that are reshaping the healthcare landscape. Understanding the dynamics at play is crucial for stakeholders to navigate this evolving market effectively.

Growth Drivers2 items

Advancements in technology have led to the development of portable and user-friendly molecular diagnostic devices, increasing their adoption at the point of care and contributing to the growth of the Molecular Diagnostics Point of Care market size.

The rising demand for rapid and accurate diagnostic results, especially in remote or resource-limited settings, is driving the demand for molecular diagnostics point of care solutions, thereby influencing the growth forecast of the market.

Restraints2 items

High development costs and the need for significant investment in research and development are acting as barriers to entry for new players, potentially limiting the expansion of the Molecular Diagnostics Point of Care market.

Stringent regulatory frameworks and the requirement for approvals from authorities such as the FDA can slow down the launch of new molecular diagnostic point of care products, affecting the market's overall growth trajectory.

Opportunities2 items

The increasing prevalence of infectious diseases and the ongoing need for effective disease management present opportunities for the Molecular Diagnostics Point of Care market to grow by offering timely and precise diagnostic solutions.

Collaborations between manufacturers and healthcare providers can lead to the development of customized point of care molecular diagnostic solutions, addressing specific needs and further expanding the market.

Challenges2 items

Ensuring the accuracy and reliability of point of care molecular diagnostic tests, especially in comparison to laboratory-based tests, is a significant challenge that manufacturers must address to gain user trust and comply with regulatory standards.

The integration of molecular diagnostics point of care devices with existing healthcare infrastructure and electronic health records systems poses a technical challenge, requiring careful consideration and strategic planning.

Market Segmentation

Loading chart…

The Application segment in the Molecular Diagnostics Point of Care market refers to the various uses of molecular diagnostics at the point of care. This includes infectious disease testing, oncology testing, and genetic testing, among others. Each application contributes to the overall market size, with infectious disease testing being the largest segment due to the high prevalence of infectious diseases globally. The Molecular Diagnostics Point of Care segmentation by application provides valuable insights into the market, helping stakeholders understand the areas of growth and investment opportunities.

The Types segment in the Molecular Diagnostics Point of Care market encompasses various subtypes, including [object Object] and [object Object]. These subtypes are further categorized into different technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). Understanding the market taxonomy of these subtypes is crucial for industry players to develop targeted strategies and products. The market size of each subtype varies, with PCR being the most widely used technology due to its high sensitivity and specificity. Analyzing the Molecular Diagnostics Point of Care market segmentation by types helps in identifying trends and patterns in the industry.

Molecular Diagnostics Point of Care Segmentation Breakdown11 items

Application

Tumor

Hematology

Endocrinology

Infectious Disease

Others

Types

Assays and Kits

Instruments and Analyzers

Software and Services

Others

Regional Insights

Loading chart…

The Molecular Diagnostics Point of Care market growth is expected to vary across regions, driven by factors such as adoption, policies, investments, demographics, infrastructure, and ecosystem maturity. North America is the largest region, accounting for approximately 40% of the market, driven by high adoption rates, favorable policies, and significant investments in healthcare infrastructure.

The fastest-growing region is Asia Pacific, driven by increasing demand for point-of-care diagnostics, growing investments in healthcare infrastructure, and a large and growing population. Europe is also a significant region, with a strong ecosystem and high adoption rates, while Latin America and Middle East & Africa are expected to experience moderate growth, driven by increasing adoption and investments in healthcare infrastructure.

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, and significant investments in healthcare infrastructure

Europe: strong ecosystem, high adoption rates, and growing demand for point-of-care diagnostics

Asia Pacific: increasing demand for point-of-care diagnostics, growing investments in healthcare infrastructure, and a large and growing population

Latin America: increasing adoption, growing investments in healthcare infrastructure, and a large and growing population

Middle East & Africa: increasing adoption, growing investments in healthcare infrastructure, and a large and growing population

Competitive Landscape

The Molecular Diagnostics Point of Care market is moderately consolidated, driven by a mix of global players and local/regional companies. The Molecular Diagnostics Point of Care competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and strategic partnerships to maintain their market position, while local companies emphasize regional expansion and cost advantages.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, and R&D investments. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Abbott Laboratories: regional expansion

Becton Dickinson and Company: innovation pipeline

Roche Diagnostics: premium pricing

Bio-Rad Laboratories: OEM tie-ups

Siemens Healthcare: vertical integration

Thermo Fisher Scientific: local manufacturing

Key Molecular Diagnostics Point of Care Companies23 items

Abbott Laboratories

Abaxis

Bayer Healthcare

Bio-Rad Laboratories

Becton Dickinson and Company

Binx Health

BioMerieux

Co-Diagnostics

Danaher Corporation

Dako

F. Hoffmann-La Roche

OraSure Technologies

Roche Diagnostics

Nipro Diagnostics

Genstat

Meridian Bioscience

Molbio Diagnostics

Siemens Healthcare

Thermo Fisher Scientific

Visby Medical

Wuhan Easy Diagnosis Biomedicine

Beijing Tiandz

Beijing Content

Market Ecosystem

The Molecular Diagnostics Point of Care ecosystem spans upstream, midstream, and downstream activities, with value created and captured through the interactions of various participants. Technology providers and suppliers deliver critical components, which are then integrated by manufacturers and system integrators. These solutions are subsequently distributed through channels to end users, who ultimately drive demand. Understanding the Molecular Diagnostics Point of Care ecosystem is essential for navigating the complex web of relationships and value flows.

Raw material/component suppliers — provide critical reagents and consumables

OEMs / manufacturers — design and produce point-of-care devices

Technology providers — develop and license diagnostic technologies

System integrators / EPCs — integrate devices with data management systems

Distributors / channel partners — deliver products to end-user facilities

Regulators/standards bodies — establish and enforce diagnostic standards

End users / buyers — purchase and utilize point-of-care diagnostic solutions

The flow of value through the ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can affect adoption rates. Dependency risks, including input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs and interoperability requirements may limit the flexibility of end users to change suppliers or integrate new solutions. As the Molecular Diagnostics Point of Care ecosystem differs by region, with varying regulatory frameworks and market conditions, understanding these nuances is crucial for effective navigation and participation.

Recent Industry Insights

The Molecular Diagnostics Point of Care industry has witnessed significant developments over the last 12-18 months, shaping the future of the Molecular Diagnostics Point of Care industry trends. Recent partnerships, such as collaborations between leading diagnostic companies and research institutions, have accelerated innovation in the field. Notable mergers and acquisitions have also taken place, enhancing the capabilities of major players. Furthermore, the launch of novel products and technologies has expanded the portfolio of point-of-care diagnostic solutions, catering to the growing demand for rapid and accurate testing.

Additionally, regulatory changes have paved the way for the adoption of molecular diagnostics at the point of care, while a shift in consumer and enterprise trends has fueled the demand for decentralized testing. The industry has also seen substantial funding rounds and expansions, underscoring the potential for growth in the Molecular Diagnostics Point of Care industry trends. These developments are expected to drive the industry forward, enabling the delivery of high-quality, patient-centric care.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Molecular Diagnostics Point of Care market outlook. The market attractiveness is high due to increasing demand for rapid and accurate diagnostic testing. The competitive intensity is moderate, with key players investing heavily in research and development to improve their market share. The long-term outlook is promising, driven by advancements in technology and growing awareness of the benefits of point-of-care testing.

The innovation landscape is rapidly evolving, with a focus on developing portable and user-friendly diagnostic devices. The demand-supply balance is expected to be stable, with manufacturers ramping up production to meet the growing demand. However, key risk factors such as regulatory challenges and reimbursement issues may impact market growth. Overall, the Molecular Diagnostics Point of Care market is poised for significant growth, driven by its potential to revolutionize the diagnostic testing landscape.

11 items

1. Executive Summary

2. Molecular Diagnostics Point of Care Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Molecular Diagnostics Point of Care Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Molecular Diagnostics Point of Care Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Tumor

6.1.2. Hematology

6.1.3. Endocrinology

6.1.4. Infectious Disease

6.1.5. Others

6.2. Global Molecular Diagnostics Point of Care Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Assays and Kits

6.2.2. Instruments and Analyzers

6.2.3. Software and Services

6.2.4. Others

6.3. Global Molecular Diagnostics Point of Care Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Molecular Diagnostics Point of Care Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Molecular Diagnostics Point of Care Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Molecular Diagnostics Point of Care Market Competition by Key Manufacturers

8.1. Global Molecular Diagnostics Point of Care Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Molecular Diagnostics Point of Care: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abaxis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bayer Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Rad Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Becton Dickinson and Company

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Binx Health

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioMerieux

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Co-Diagnostics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Danaher Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Dako

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. F. Hoffmann-La Roche

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. OraSure Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Roche Diagnostics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Nipro Diagnostics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Genstat

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Meridian Bioscience

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Molbio Diagnostics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Siemens Healthcare

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Thermo Fisher Scientific

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Visby Medical

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Wuhan Easy Diagnosis Biomedicine

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Beijing Tiandz

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Beijing Content

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Molecular Diagnostics Point of Care Market

Figure 4: Global Molecular Diagnostics Point of Care Market: Drivers

Figure 5: Global Molecular Diagnostics Point of Care Market: Challenges

Figure 6: Global Molecular Diagnostics Point of Care Market: Trends

Figure 7: Global Molecular Diagnostics Point of Care Market: Opportunity

Figure 8: Global Molecular Diagnostics Point of Care Market: Restraint

Figure 9: Global Molecular Diagnostics Point of Care Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Molecular Diagnostics Point of Care Market Value (USD Million) By Region

Figure 15: Global Molecular Diagnostics Point of Care Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Molecular Diagnostics Point of Care Market Value (USD Million) By Region

Figure 23: Global Molecular Diagnostics Point of Care Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Molecular Diagnostics Point of Care Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Molecular Diagnostics Point of Care Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Molecular Diagnostics Point of Care Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Molecular Diagnostics Point of Care Market Value (USD Million) By Region

Table 10: Global Molecular Diagnostics Point of Care Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Molecular Diagnostics Point of Care Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Molecular Diagnostics Point of Care Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Molecular Diagnostics Point of Care Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Abaxis Basic Information And Sales Area

Table 33: Abaxis. Products Portfolio

Table 34: Bayer Healthcare Basic Information And Sales Area

Table 35: Bayer Healthcare. Products Portfolio

Table 36: Bio-Rad Laboratories Basic Information And Sales Area

Table 37: Bio-Rad Laboratories. Products Portfolio

Table 38: Becton Dickinson and Company Basic Information And Sales Area

Table 39: Becton Dickinson and Company. Products Portfolio

Table 40: Binx Health Basic Information And Sales Area

Table 41: Binx Health. Products Portfolio

Table 42: BioMerieux Basic Information And Sales Area

Table 43: BioMerieux. Products Portfolio

Table 44: Co-Diagnostics Basic Information And Sales Area

Table 45: Co-Diagnostics. Products Portfolio

Table 46: Danaher Corporation Basic Information And Sales Area

Table 47: Danaher Corporation. Products Portfolio

Table 48: Dako Basic Information And Sales Area

Table 49: Dako. Products Portfolio

Table 50: F. Hoffmann-La Roche Basic Information And Sales Area

Table 51: F. Hoffmann-La Roche. Products Portfolio

Table 52: OraSure Technologies Basic Information And Sales Area

Table 53: OraSure Technologies. Products Portfolio

Table 54: Roche Diagnostics Basic Information And Sales Area

Table 55: Roche Diagnostics. Products Portfolio

Table 56: Nipro Diagnostics Basic Information And Sales Area

Table 57: Nipro Diagnostics. Products Portfolio

Table 58: Genstat Basic Information And Sales Area

Table 59: Genstat. Products Portfolio

Table 60: Meridian Bioscience Basic Information And Sales Area

Table 61: Meridian Bioscience. Products Portfolio

Table 62: Molbio Diagnostics Basic Information And Sales Area

Table 63: Molbio Diagnostics. Products Portfolio

Table 64: Siemens Healthcare Basic Information And Sales Area

Table 65: Siemens Healthcare. Products Portfolio

Table 66: Thermo Fisher Scientific Basic Information And Sales Area

Table 67: Thermo Fisher Scientific. Products Portfolio

Table 68: Visby Medical Basic Information And Sales Area

Table 69: Visby Medical. Products Portfolio

Table 70: Wuhan Easy Diagnosis Biomedicine Basic Information And Sales Area

Table 71: Wuhan Easy Diagnosis Biomedicine. Products Portfolio

Table 72: Beijing Tiandz Basic Information And Sales Area

Table 73: Beijing Tiandz. Products Portfolio

Table 74: Beijing Content Basic Information And Sales Area

Table 75: Beijing Content. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global Molecular Diagnostics Point of Care Market Value (USD Million) By Region

Table 81: Global Molecular Diagnostics Point of Care Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Molecular Diagnostics Point of Care Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	23.60 million
Revenue forecast in 2033	46.68 million
Growth rate	CAGR of 8.9% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Abaxis; Bayer Healthcare; Bio-Rad Laboratories; Becton Dickinson and Company; Binx Health; BioMerieux; Co-Diagnostics; Danaher Corporation; Dako; F. Hoffmann-La Roche; OraSure Technologies; Roche Diagnostics; Nipro Diagnostics; Genstat; Meridian Bioscience; Molbio Diagnostics; Siemens Healthcare; Thermo Fisher Scientific; Visby Medical; Wuhan Easy Diagnosis Biomedicine; Beijing Tiandz; Beijing Content
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Molecular Diagnostics Point of Care Segmentation Breakdown11 items

Application

Tumor

Hematology

Endocrinology

Infectious Disease

Others

Types

Assays and Kits

Instruments and Analyzers

Software and Services

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, and significant investments in healthcare infrastructure

Europe: strong ecosystem, high adoption rates, and growing demand for point-of-care diagnostics

Asia Pacific: increasing demand for point-of-care diagnostics, growing investments in healthcare infrastructure, and a large and growing population

Latin America: increasing adoption, growing investments in healthcare infrastructure, and a large and growing population

Middle East & Africa: increasing adoption, growing investments in healthcare infrastructure, and a large and growing population

Competitive Landscape

Abbott Laboratories: regional expansion

Becton Dickinson and Company: innovation pipeline

Roche Diagnostics: premium pricing

Bio-Rad Laboratories: OEM tie-ups

Siemens Healthcare: vertical integration

Thermo Fisher Scientific: local manufacturing

Key Molecular Diagnostics Point of Care Companies23 items

Abbott Laboratories

Abaxis

Bayer Healthcare

Bio-Rad Laboratories

Becton Dickinson and Company

Binx Health

BioMerieux

Co-Diagnostics

Danaher Corporation

Dako

F. Hoffmann-La Roche

OraSure Technologies

Roche Diagnostics

Nipro Diagnostics

Genstat

Meridian Bioscience

Molbio Diagnostics

Siemens Healthcare

Thermo Fisher Scientific

Visby Medical

Wuhan Easy Diagnosis Biomedicine

Beijing Tiandz

Beijing Content

Market Ecosystem

Raw material/component suppliers — provide critical reagents and consumables

OEMs / manufacturers — design and produce point-of-care devices

Technology providers — develop and license diagnostic technologies

System integrators / EPCs — integrate devices with data management systems

Distributors / channel partners — deliver products to end-user facilities

Regulators/standards bodies — establish and enforce diagnostic standards

End users / buyers — purchase and utilize point-of-care diagnostic solutions

Recent Industry Insights

Analyst Overview

Table of Contents